共 212 条
[1]
Nishimura T(2005)Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements Clin Exp Hypertens 27 477-489
[2]
Hashimoto J(2012)Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension Clin Exp Hypertens 34 86-91
[3]
Ohkubo T(2016)Azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects: a review study Front Pharmacol 7 235-1515
[4]
Kikuya M(2011)Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension Ann Pharmacother 45 1506-188
[5]
Metoki H(2016)Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study Clin Exp Hypertens 38 180-143
[6]
Asayama K(2012)Differential pharmacology and benefit/risk of azilsartan compared to other sartans Vasc Health Risk Manag 8 133-111
[7]
Totsune K(2017)Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: a randomized, open-label study J Pharmacol Pharmacother 8 106-341
[8]
Imai Y(2016)Persistent olmesartan-based blood pressure-lowering effects on morning hypertension in Asians: the HONEST study Hypertens Res 39 334-274
[9]
Hasegawa H(2017)Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan-based treatment High Blood Press Cardiovasc Prev 24 265-74
[10]
Takano H(2016)A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients Int J Cardiol 221 60-420